These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16990410)

  • 1. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension.
    Zhu S; Su G; Meng QH
    Clin Chem; 2006 Nov; 52(11):2036-42. PubMed ID: 16990410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
    Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L
    Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials.
    Ramjattan BR; Callaghan DJ; Theiss U
    Clin Ther; 2002 Jul; 24(7):1105-16. PubMed ID: 12182255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
    Ansquer JC; Foucher C; Rattier S; Taskinen MR; Steiner G;
    Am J Kidney Dis; 2005 Mar; 45(3):485-93. PubMed ID: 15754270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micronized fenofibrate: a new fibric acid hypolipidemic agent.
    Guay DR
    Ann Pharmacother; 1999 Oct; 33(10):1083-103. PubMed ID: 10534222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Other antihyperuricemic agents].
    Ogino K; Igawa O; Hisatome I
    Nihon Rinsho; 2008 Apr; 66(4):754-7. PubMed ID: 18409527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.
    Sharpe M; Ormrod D; Jarvis B
    Am J Cardiovasc Drugs; 2002; 2(2):125-32; discussion 133-4. PubMed ID: 14727988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niacin, fenofibrates increase benefits for statin users. These HDL- raising, triglyceride-lowering drugs beat out the use of additional LDL-lowering drugs.
    Duke Med Health News; 2010 Aug; 16(8):1-2. PubMed ID: 20799416
    [No Abstract]   [Full Text] [Related]  

  • 10. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyte suppressing action of fenofibrate.
    Okopień B; Kowalski J; Krysiak R; Łabuzek K; Stachura-Kułach A; Kułach A; Zieliński M; Herman ZS
    Pharmacol Rep; 2005; 57(3):367-72. PubMed ID: 15985720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy.
    Harmer JA; Keech AC; Veillard AS; Skilton MR; Watts GF; Celermajer DS;
    Diabetes Res Clin Pract; 2018 Jul; 141():156-167. PubMed ID: 29763709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
    Vakkilainen J; Steiner G; Ansquer JC; Aubin F; Rattier S; Foucher C; Hamsten A; Taskinen MR;
    Circulation; 2003 Apr; 107(13):1733-7. PubMed ID: 12665498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome.
    Wysocki J; Belowski D; Kalina M; Kochanski L; Okopien B; Kalina Z
    Int J Clin Pharmacol Ther; 2004 Apr; 42(4):212-7. PubMed ID: 15124979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Kontopoulos AG
    Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of plasma ox-LDL and carotid IMT may represent useful markers for atherosclerosis and may represent potential targets for therapeutic interventions.
    Savoiu G; Drăgan S; Cristescu C; Serban C; Noveanus L; Ionescu D; Nicola T; Duicu O; Raducan A; Voicu M
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):397-401. PubMed ID: 21491821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia].
    Li LJ; Chen H; Ren JY; Wang L; Luo Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):541-4. PubMed ID: 19829670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.